The enormous progress in proteomics, enabled by recent advances in MS (mass spectrometry), has brought protein analysis back into the limelight of cancer research, reviving old areas as well as opening new fields of study. In this review, we discuss the basic features of proteomic technologies, including the basics of MS, and we consider the main current applications and challenges of proteomics in cancer research, including (i) protein expression profiling of tumours, tumour fluids and tumour cells; (ii) protein microarrays; (iii) mapping of cancer signalling pathways; (iv) pharmacoproteomics; (v) biomarkers for diagnosis, staging and monitoring of the disease and therapeutic response; and (vi) the immune response to cancer. All these applications continue to benefit from further technological advances, such as the development of quantitative proteomics methods, high-resolution, high-speed and high-sensitivity MS, functional protein assays, and advanced bioinformatics for data handling and interpretation. A major challenge will be the integration of proteomics with genomics and metabolomics data and their functional interpretation in conjunction with clinical results and epidemiology.
INTRODUCTION
Proteomics seems to have mesmerized current scientific thinking, taking over centre stage from the genome projects. How important is proteomics for cancer research? Consulting Medline reveals that, since 1997, when the word proteomics first appeared as an entry, approx. 0.12 % of all articles on cancer also contain the word proteomics. Comparing this frequency with the occurrence of the search string 'genomics' in 0.17 % of the cancer literature, it becomes obvious that proteomics has attracted major scientific attention in the field of cancer research. Vice versa, a search for 'cancer AND proteomics' shows that 16 % of the proteomics literature deals with cancer, testifying that the attraction is mutual. What is behind that love affair?
The sequencing of the human genome has confronted us with the daunting task of explaining the myriad of physiological and pathological functions of a highly complex and adaptable organism by a mere 40 000 odd genes. Clearly, a 'one gene -one function' relationship does not apply. Even worse, due to differential splicing and translation, each human gene may encode four to six different proteins. Taking into account the numerous PTMs (post-translational modifications), our 40 000 genes may generate around 1 million distinguishable functional entities at the protein level. Hence there are many good reasons to tackle the proteome. Although of vexing complexity, it in principle offers a much richer source for the functional description of diseases and the discovery of diagnostic and therapeutic targets. An additional and unique advantage is that, in contrast with the genome, the inherently dynamic nature of the proteome allows us to monitor closely changes in the state of a cell, tissue or organism over time. Only dynamic information will allow us to follow the course of a disease and track its pathogenetic mechanisms as well as its response to therapy. This may be of particular importance for diseases such as cancer, which evolve dynamically and affect many heterogeneous cell populations, either as part of the cancer or as part of the host's reaction to the tumour. A key question is whether we will be able to master and exploit the complexity of the proteome. In this review, rather than trying to give an exhaustive account of the extensive literature, we will focus on discussing current questions and developments in proteomics that are pertinent to cancer research.
BASICS OF MS (MASS SPECTROMETRY)
Proteomics has been enabled by breakthrough advances in MS that expanded the use of MS beyond the analysis of small molecules to peptides and proteins. The use of MS for protein analysis was the topic of an excellent recent review [1] , hence we only briefly discuss the most relevant features here ( Figure 1 ). MS instruments consist of at least two basic components: an ionization module and a mass analyser. The ionization module confers electrical charges to the molecules to be analysed, typically by adding protons, thus generating ions that can move in the electromagnetic fields of the mass analyser. Ion movement is dependent on the mass and charge of the ion, and can be measured as mass over charge (m/z) ratio. Hence the true mass can only be determined if the charge state can be determined, which requires the resolution of naturally occurring isotopic variants. This becomes more difficult with increasing size and charge state and, in addition, the accuracy and sensitivity of measurements decrease as mass increases, confining MS to the analysis of relatively small molecules. The routine analysis of larger molecules, such as peptides, became feasible with the advances in ionization techniques that have become the mainstay of MS in proteomics. The importance of these innovations is well reflected in the award of the 2002 Nobel Prize for Chemistry to Koichi Tanaka and John Fenn for their invention of MALDI (matrix-assisted laser-desorption ionization) and ESI (electrospray ionization) respectively.
MS is capable of deducing the composition of molecules by determining their mass with high accuracy. For example, a particular peptide mass can only be composed from certain combinations of amino acids. The higher the accuracy of the mass measurements the less ambiguous is the assignment of composition. However, as sensitivity and mass accuracy fall off sharply with increasing size, the most effective mass window of MS lies between 1-5 kDa. For analysis, therefore, proteins are typically digested with trypsin or another specific protease to generate peptides small enough to be amenable to MS analysis. This method is often referred to as PMF (peptide mass fingerprinting). For additional confidence, the controlled fragmentation of a peptide within the mass spectrometer, yielding a series of overlapping fragment ions that differ by the mass of a particular amino acid, permits the deduction of a full or partial amino acid sequence of the peptide. This operation is often referred to as MS/MS or tandem MS experiment as it typically uses one MS analyser to select the ion to be fragmented and a second to measure the fragment ions.
MS has revolutionized protein identification, pushing sensitivity by several orders of magnitude and shortening the process from many hours to a few minutes. In combination these advantages now permit the identification of several hundred proteins per day per MS instrument. However, it is also important to note the limitations of MS. The sensitivity of MS is crucially dependent on ionization efficiency, which is determined by the purity and primary sequence of the peptide to be analysed. This has a number of important implications. As peptides compete for ionization, sensitivity increases as the complexity of the sample decreases. In particular, if the sample is dominated by a number of highly abundant peptides, it can be difficult to detect low abundance peptides. This is the typical situation for serum or plasma samples where the protein concentration varies over more than 11 orders of magnitude. Thus the efficiency and quality of the protein pre-separation is as important as the MS analysis itself. Because of different ionization efficiencies, the sensitivities at which different peptides are detected vary widely. Thus MS is non-quantitative, but permits relative comparisons between identical peptides. This is exploited by the new mass tag approaches where samples to be compared are labelled with a 'heavy' or a 'light' mass tag respectively, and mixed together before MS analysis. The characteristic mass difference caused by the mass tag permits the relative quantitative comparison between identical peptides from the samples in the MS analysis A survey scan measures the peptide masses, which are assembled into a peak list for database searches. The search engine compares the peptide masses with a theoretical peptide digest of the database and identifies proteins that match the measured masses. Several matching peptide masses are required for a statistically significant identification. Right-hand panel, determination of peptide sequence. This procedure requires a tandem MS. Using MS1, the peptide peak to be sequenced is selected from the survey scan and fragmented, usually by collision with gas. The fragment masses are determined by MS2. The peptide sequence can be deduced from the fragment masses. Note that the fragmentation is not homogenous with missing fragments precluding the deduction of the complete peptide sequence. Therefore, rather than trying to read the sequence from the mass spectrum, the fragmentation pattern is usually submitted to a database search engine which compares the observed pattern with theoretically expected peptide fragmentation patterns of the proteins in the database. Thus the peptide sequence, and in most cases the identity of the protein, can be inferred. and the concomitant identification of the parent protein.
The identification of a protein is typically based on matching the masses of peptides or peptide fragments to theoretical digests or fragmentation patterns of protein databases. Thus good databases are a prerequisite to interpret MS data. The robustness of protein identification increases with the accuracy of the mass measurements and the number of detected peptides that belong to the same protein. All commonly used search engines assign a statistical significance score to the identification, but in borderline cases manual inspection of the data by an expert is highly advisable. MS can also identify PTMs as they cause a characteristic mass shift. However, the peptides identified by MS and assigned to a protein rarely cover the entire protein sequence. Consequently, although MS is very powerful in identifying PTMs, it does not guarantee an exhaustive analysis. The prolific development of MS combining different types of ionization and mass analyser modules has resulted in a variety of instruments optimized for different purposes. However, as there is no single instrument that can do it all, state of the art proteomics facilities need to be equipped with several different types of MS instruments.
PROTEIN EXPRESSION PROFILING OF TUMOURS, TUMOUR FLUIDS AND TUMOUR CELLS
The first step in any proteomic analysis is always a protein separation, and there is a wealth of methods to choose from, each with advantages and disadvantages. Thus the selection will depend on the scientific question, the sample material, available equipment and expertise. We will discuss the most commonly used methods; typical proteomic workflows are shown in Figure 2 .
2DGE (two-dimensional gel electrophoresis)
For more than 30 years the mainstay of protein expression profiling has been 2DGE, where proteins are separated according to their isoelectric point using isoelectric focussing in the first dimension, and by size using SDS/PAGE in the second dimension. The introduction of immobilized pH gradients and advanced bioinformatics have vastly improved the reproducibility and comparability between gels, although the high demand on labour is a serious obstacle to 2DGE becoming routine for a clinical laboratory [2] . However, for research purposes, 2DGE is still extremely valuable. Many studies have been performed showing that 2DGE can detect differences between normal and cancer cell proteomes, although the extent of these changes appears quite variable. For instance, in breast cancer only few differences were observed in some studies [3] , whereas others found numerous changes that could be used to distinguish normal, benign and malignant tumours by hierarchical clustering [4, 5] . The reasons for these discrepancies are not entirely clear, but are more probably due to differences in sample acquisition and preparation and protein staining and quantification than the performance of the 2DGE.
The quantification of proteins has now become very accurate with the introduction of highly sensitive fluorescent stains with a wide dynamic range, technology that has been very effectively employed in DiGE (differential gel electrophoresis) [6] . In DiGE, the protein samples to be compared are covalently labelled with a green or red fluorescent dye respectively. A mixture of all of the samples in the study is then labelled with a blue dye to serve as an internal standard. All three samples are then mixed together and separated by 2DGE. This avoids ambiguities of spot matching as the samples are separated on the same gel, and intergel comparisons are greatly improved by the common internal standard. The individual samples are displayed by scanning the gel at the three distinctive wavelengths. Since the fluorescence signal is linear over a wide protein concentration range and each spot contains its own internal standard, comparative quantification is very accurate. In addition, the sensitivity is comparable with silver staining, but in contrast with silver staining, fluorescent stains are fully MS compatible. DiGE has recently been used to profile protein expression in six human colon cancers and adjacent normal mucosa [7] . Of over 1500 protein spotfeatures analysed in each paired normal/tumour sample, 52 differentially expressed proteins were identified by MS. Because of the large inherent variation between normal and tumour samples, 80 % of these proteins would have been overlooked without the internal 'blue' standard. Another study integrated DiGE with an automated robotic spot handling workstation to profile protein expression in different stages of human breast IDCA (infiltrating ductal carcinoma) to non-neoplastic tissue [8] . Quantitative differences in protein abundance ranging from 14.8 % in stage I IDCA to 30.6 % in stage IIB IDCA versus normal were detected. Out of 524 proteins that showed a 3-fold difference in abundance between IDCA and normal tissue, approx. 80 % were identified by MS. However, only the overexpression of Hsp70 (heat-shock protein 70) and the reduction of peroxiredoxin-2 proved consistent in all the IDCAs examined. Although these studies attest to the power of DiGE, they also demonstrate the vast heterogeneity of tumour samples and reinforce the quest for better separation methods.
2DGE can resolve 1500-3000 protein spots per gel, which is still at the top end of any two-step separation procedure. By spreading the pH range across several gels, so called zoom gels [9] , between 5000-10 000 protein spots can be resolved. This is no surprise as the proteome of cells may comprise up to a million different protein species. Hence any additional purification step will display more proteins. In this respect, subcellular fractionation offers the advantage of well-established protocols for many subcellular compartments and additional information derived from protein localization [10] . For instance, plasma membrane microdomains, so called lipid rafts, were isolated, separated by standard SDS/PAGE and analysed by quantitative MS/MS [11] . Among the 241 proteins identified as bona fide raft components, signalling proteins were highly enriched, confirming that rafts serve as signal transduction platforms. Similarly, more than 500 membrane resident proteins were identified from breast cancer cell membrane preparations that were separated by SDS/PAGE and analysed by MS/MS [5] . These comprised both high-and low-abundance proteins, with one-third being of unknown function. Three of the latter proteins were examined further and shown to be overexpressed in a significant number of human breast cancer samples.
A powerful approach is the combination of subcellular fractionation with 2DGE [10] . This has been elegantly demonstrated by a recent study that compared protein expression in endothelial cell surfaces isolated from lung and solid tumours in a rat model [12] . The authors found significant differences in the protein expression patterns in endothelial surfaces between normal organs and tumour xenografts, suggesting that the transplanted tumour can profoundly alter protein expression in the tumour blood vessels supplied by the host. Importantly, two proteins, aminopeptidase-P and annexin A1, were identified as selectively expressed in lungs and solid tumours respectively, and accessible to antibodies. Aminopeptidase-P was identified previously as the endothelial cell-surface receptor for a peptide that could direct phage particles to selectively home to the breast vasculature including breast tumours [13] . The functional significance of aminopeptidase-P expression in tumour blood vessels is unknown. Intriguingly, aminopeptidase-P cleaves and inactivates bradykinin, a peptide implicated in tumorigenesis mainly via the regulation of vascular permeability and neoangiogenesis [14] . Links between tumorigenesis and annexin A1 expression are more firmly established. Annexin A1 expression may help maintain normal epithelial architecture as its expression is downregulated in many epithelial tumours, including tumours of the oesophagus [15] , breast [16] , head and neck [17] , and prostate [18] . On the other hand, annexin A1 expression was correlated with poorly differentiated pancreatic adenocarcinoma [19] . It is yet unclear why annexin A1 expression was selectively found to be upregulated in the endothelium of the tumour vasculature in the xenografts model described by Oh et al. [12] . However, the injection of radiolabelled antibodies against annexin A1 destroyed tumours and extended animal survival [12] . Thus the combination of subcellular fractionation with 2DGE and MS has identified tissueand disease-specific endothelial cell-surface proteins that can serve as antibody accessible targets useful for imaging and therapy.
Another useful approach is the combination of LMD (laser microdissection) and proteomics, although it is very challenging to obtain sufficient cells for 2DGE. Using up to 100 000 microdissected epithelial cells or whole tissue sections for 2DGE, matched normal ductal/lobular units and DCIS (ductal carcinoma in situ) of the human breast were compared [20] . Fifty-seven differentially expressed proteins could be identified by MS, of which ten were validated in independent DCIS specimens. In addition, 14 of 15 quantitative 2DGE trends were confirmed by IHC (immunohistochemistry). Many of these proteins had not been previously linked to breast cancer, including proteins regulating intracellular trafficking, chaperone function, cytoskeleton, apoptosis and genome stability. DiGE applied to the comparison of the proteome of normal intestinal epithelium with that of adenoma in the Min mouse intestinal cancer model enabled the visualization of approx. 1500 protein spots from only 6.6 µg of material [21] . This is about 10-fold less than required for a standard 2DGE experiment, and still permitted the identification of eight out of 37 differentially expressed spots.
Chromatographic methods
A limitation of 2DGE is the under-representation of very basic and hydrophobic membrane proteins that are lost due to poor solubility in 2DGE-compatible lysis buffers, or precipitation at their isoelectric point in the first dimension. The membrane protein compartment is of high interest, especially in cancer research, where many alterations affect cell-surface proteins and receptors. Improvements in 2DGE of membrane proteins have been made [22] , and alternative methods have been developed. A promising approach is MudPIT (multidimensional protein identification technology) [23] . It uses sequential cation exchange and reverse-phase chromatography for two-dimensional separation, avoiding gels and many of the difficulties encountered with membrane proteins. MudPIT also directly interfaces with MS, dramatically cutting down analysis time. However, as MS compatible chromatographic systems can only handle small peptides, the samples must be digested with a protease, typically trypsin, before analysis. The resulting vast increase in complexity currently forfeits any decisive increase in the number of proteins identifiable. However, as most proteins contain at least some peptides that are well amenable to MS analysis, MudPIT reduces the bias against the detection of basic and hydrophobic proteins. Advances achieving better representation of low-abundance proteins and quantitative comparisons have been made by combining MudPIT with ICAT (isotope-coded affinity tags) [24] , a form of mass tags that modify cysteine residues and permit the affinity purification of tagged peptides. This reduces the complexity of the peptide sample that has to be analysed. A proof of principle experiment quantitatively compared protein expression in microsomal membranes of naïve and differentiated HL-60 cells [25] . The application of this technology to compare microdissected hepatocellular carcinoma with normal hepatocytes demonstrated its feasibility for the analysis of clinical samples. It identified 644 proteins, of which 261 were unambiguously quantified [26] .
PROTEIN MICROARRAYS
Another area of intense research is the development of protein arrays that, similar to gene arrays, would allow us to study changes in protein expression or modification on a global scale without much of the specialist and expensive equipment required by MS-based proteomics. There are two basic designs, (i) FPAs (forward phase arrays), where antibodies are arrayed and probed with cell lysates, or (ii) RPAs (reverse phase arrays), where cell lysates are arrayed and probed with antibodies [27] . Formidable technical obstacles have to be overcome to construct robust protein arrays. In contrast with nucleic acids, proteins are much less structurally stable and differ vastly in their physicochemical properties, such as affinity towards their interaction partners and retention of function when deposited on an array. Therefore only a few studies have been performed, and most of them have employed FPAs (antibody arrays). Currently, their main limitations are low sensitivity and high variability [28] . Nevertheless, they are starting to be used in clinical settings. An FPA containing 378 monoclonal antibodies was employed to compare the protein expression in malignant and adjacent normal human breast tissue. The expression of a number of proteins, including casein kinase I, p53, annexin XI, CDC25C, eIF-4E and MAPK (mitogen-activated protein kinase) 7, was increased in the tumour, and subsequently confirmed by IHC [29] . RPAs have achieved the sensitivity and reliability acceptable for the analysis of clinical specimens. However, they need to be custom made for each sample, and usually are not printed in large numbers, making their production tedious and expensive. They are currently mainly employed for functional studies with antibodies that recognize PTMs. Screening LMD ovarian tumour cell lysates with phospho-specific antibodies showed that advanced stage tumours had slightly higher levels of phosphorylated ERK1/2 (extracellular-signal-regulated kinase 1/2) compared with early stage tumours. However, the levels of activated ERK1/2 varied considerably without any significant correlation with histological types. Similar results were obtained when assaying for activated Akt and GSK 3β (glycogen synthase kinase 3β), suggesting that, in ovarian cancer, signalling pathways may be activated in a patient-specific, rather than type-or stage-specific, pattern [30] . Ongoing clinical research trials at the National Cancer Institute, U.S.A., are using RPAs to study phosphorylation and proteolytic cleavage of selected proteins in the EGF (epidermal growth factor)-receptor family pathways. Besides evaluating the technology, especially with respect to sample procurement and processing, the ultimate goal is to match cancer patients to an individualized combination therapy according to their molecular signalling protein activation profiles [31] .
MAPPING OF CANCER SIGNALLING PATHWAYS
Cancer can be considered as a disease of communication at the molecular and cellular level. Aberrations in signal transduction pathways go hand in hand with genetic instability, and both are observed consistently in cancer [32] . Although genetic mutations ultimately underlie most aberrations in signalling pathways, their effects on cell physiology can only be understood at the level of protein function. Therefore there is a keen interest in studying protein function on a global scale. The vast complexity and dynamic range of protein expression have hampered these efforts, as low-abundant proteins often escape detection. Unfortunately, many regulatory proteins such as transcription factors or signalling proteins are of low abundance, and proteomics is struggling to overcome these hurdles. A promising approach that can reach low-abundance proteins and determine their functional state is the analysis of protein complexes complemented by the analysis of PTMs.
Protein interactions
The large-scale road mapping of signalling pathways became possible when it was recognized that pathways are organized as interacting units of protein complexes that form the physical machines for signal processing and serve as communication platforms between pathways. The first, and still very successful, technology was the Y2HS (yeast two-hybrid system), which detects protein interactions through screening for a selectable protein function that is reconstituted by the interaction of the partners. Benefiting from the sophisticated tools of yeast genetics, the Y2HS has evolved into a powerful method that has been used to start developing comprehensive protein interaction maps of model organisms such as yeast, Drosophila melanogaster and Caenorhabditis elegans [33] . Y2HS interaction maps of human disease relevant pathways are also being generated; for instance, the TGFβ/SMAD signalling pathway (where TGF is transforming growth factor) has been mapped [34] . The main limitations of Y2HS are that it can only detect direct and binary interactions, that the interactions take place in a rather non-physiological environment, and that it only permits a very limited analysis of interactions that are formed or broken in response to different cellular conditions.
Interaction mapping by MS-based proteomics approaches overcomes these restrictions, and hence has become increasingly attractive, especially for functional studies. For instance, signalling complexes formed by the EGF receptor during EGF stimulation were analysed by quantitative MS-based proteomics, revealing functional relationships and the dynamics of EGFreceptor-mediated events during the early phase of signalling [35] . Besides advanced MS methods, the key factor to success is a specific, rapid and efficient protocol to isolate protein complexes. Thus a typical approach is to fuse the protein of interest to a tag that permits the easy and efficient isolation of the protein and its interaction partners for subsequent MS analysis. A variation of this theme that improves specificity is the TAP (tandem affinity purification) tag [36] . The TAP tag uses two tags separated by a cleavage site for the highly specific TEV (tobacco etch virus) protease. After affinity purification using the first tag, the complex is released by TEV cleavage and re-isolated using the second tag. This procedure yields complexes of high purity, although it is less well suited to study transient and dynamic changes, as the isolation takes several hours, favouring the isolation of stable complexes.
The isolation of protein complexes, and subsequent identification of their components by MS, is now well established and lends itself to the development of functional screens. For instance, characterizing the interaction partners of mitochondrial ANT (adenine nucleotide translocator) in cells treated with chemotherapeutic drugs unveiled a number of interactions that changed strongly and concomitantly with the onset of apoptosis [37] . These included Bax, Bcl2, subunits of the respiratory chain, a subunit of the phosphatase PP2A, phospholipase Cβ4 and the inositol 1,4,5-trisphosphate receptor, and the shift from a core ANT-Bcl2 complex in normal cells to a core ANT-Bax complex in apoptotic cells. This change in allegiance from the anti-apoptotic Bcl2 to the proapoptotic Bax seemed to be at the heart of the dynamic changes in the ANT interactome that coordinate druginduced apoptosis. Deciphering interaction proteomes can be integrated with other functional assay systems for the development of highly creative screening strategies. One such strategy has identified extracellular Hsp90α as a crucial activator of MMP-2 (metalloproteinase-2) and required for cancer cell invasion [38] . This work used antibody libraries to inactivate extracellular membrane structures required for invasion. Antibodies that interfered with invasion were subsequently used to purify the cognate protein antigens responsible for invasive behaviour and identify them by MS.
PTMs
Protein function is often regulated by PTMs. Thus deciphering PTMs and their dynamic changes can reveal the functional state of signalling pathways. As PTMs cause a characteristic shift in mass, MS is, in principle, ideally suited for the identification of PTMs. However, sequence coverage of a protein by MS analysis is rarely complete, hence PTMs occurring outside the covered sequence will be missed. In addition, some PTMs reduce ionization efficiency and hence sensitivity, or are labile and are lost during fragmentation. The former disadvantage applies to phosphorylation and the latter to serine/threonine phosphorylation in particular, although this can be turned to advantage using precursor ionscanning MS experiments [39] . Unfortunately, phosphorylation is one of the most common and important PTMs, and improvements in the MS analysis of phosphorylation sites are being pursued vigorously [40] . The ability of phosphate groups to bind to chelated iron or gallium can be used to enrich phosphopeptides by IMAC. However, poor and non-specific binding, and inefficient elution of the phosphopeptides warranted further improvements. Methylation of the peptide mixture before IMAC reduces the non-specific retention of acidic peptides [41] , while improvements in the MS methodology have enhanced the sensitivity of detection of phosphorylated species [42, 43] . Interesting variations are to chemically replace the phosphate group with a biotin affinity tag in order to permit the selective isolation of the derivatized peptide [44] , or to mark the phosphorylation sites by chemically converting phosphoserine and phosphothreonine residues into lysine analogues (aminoethylcysteine and β-methylaminoethylcysteine respectively), which can then be cleaved with a lysine-specific protease and detected by MS [45] . Although elegant the chemical methods currently suffer from technical problems, such as the complexity and incompleteness of the chemical reactions, and the requirement for large amounts of starting material. Stains have been developed for visualizing phosphoproteins in gels or on blots [46] , which in conjunction with glycosylation-specific stains can even be used to monitor changes in phosphorylation and glycosylation simultaneously [47] . These stains are MS compatible and potentially immensely useful, but have not yet been widely tested.
PHARMACOPROTEOMICS
The majority of drug targets are proteins. However, we currently only exploit around 500 out of the estimated > 3000 proteins that are predicted to be druggable [48] . Proteomics has become an important tool for the discovery of new targets, and the further characterization of known drug targets with unknown function. Proteomics approaches for the analysis of protein expression and PTMs are also very useful for the investigation of the cellular responses to drugs, and to study their mechanism of action and the basis of resistance [49] .
Very rarely can the full spectrum of biological responses to a drug be explained by its specificity for a single target, suggesting the existence of other important targets. Using immobilized drugs as baits to isolate these additional targets, they can be identified by MS. Such an approach has, for instance, identified new target proteins of the widely used p38 MAPK inhibitor SB 203580 [50] and bisindolylmaleimide PKC (protein kinase C) inhibitor GF109203X [51] . The identification of such a set of target proteins is equally powerful for elucidating the molecular basis for side effects as well as opening new potential applications for a known drug.
The immediate clinical relevance of this approach is demonstrated by the case of imatinib mesylate. Developed as a BCR-ABL inhibitor it showed spectacular effects against CML (chronic myeloid leukaemia), a disease hallmarked by the t(9;22) chromosomal translocation which gives rise to the expression of the BCR-ABL oncoprotein. Unfortunately, gene amplification or mutations in BCR-ABL can cause imatinib resistance, and new treatments to overcome drug resistance are needed [52] . Tyrosine kinase inhibitors of the pyrido- [2,3-d] pyrimidine class are effective against most of the imatinib-resistant BCR-ABL mutants found in CML. Using immobilized pyrido [2,3-d] pyrimidine as an affinity bait, MS identified more than 30 human protein kinases interacting with these compounds [53] . Amongst the most effective targets were two serine/ threonine kinases, RICK (Rip-like interacting caspaselike apoptosis-regulatory protein kinase) and p38α, surprisingly showing that pyrido [2,3-d] pyrimidines can inhibit tyrosine and serine/threonine kinases alike. Their selectivity turned out to be determined by a conserved small amino acid residue in a critical site of the ATPbinding pocket. As BCR-ABL suppresses p38 activation and imatinib-induced apoptosis requires p38 activity [54, 55] , the p38 inhibitory action of pyrido [2,3-d] pyrimidines would be expected to reduce their therapeutic efficacy against CML despite antagonizing BCR-ABL mutants. Thus, in this case, proteomics not only revealed other drug targets that could be crucial for the therapeutic effect and shed light on the mechanism of inhibition, but also made direct suggestions for improvements in drug design and therapeutic applications. Either reducing the inhibition of p38 through pharmacological design or combining pyrido [2,3-d] pyrimidines with p38 activators should enhance the therapeutic efficacy in CML.
Another elegant example for the power of functional proteomics based approaches is the identification of new drug targets in the TOR (target of rapamycin) pathway [56] . TOR proteins are central to nutrient signalling and transformation pathways, and rapamycin causes growth arrest resembling nutrient starvation. Screening a drug library for the modification of the growth response to rapamycin in yeast identified two classes of drugs; SMIRs (small-molecule inhibitors of rapamycin) and SMERs (small-molecule enhancers of rapamycin). These compounds were subsequently used to probe yeast protein microarrays with the aim to identify the target proteins for these drugs. SMIR targets included a homologue of the mammalian PTEN (phosphatase and tensin homologue deleted on chromosome 10) tumour suppressor protein, demonstrating how the combination of a functional biological screen with proteomics can identify both new drugs and their targets.
BIOMARKERS
Clinical chemistry routinely makes very extensive and successful use of biomarkers, such as cholesterol, glucose levels etc., to help determine and monitor a patient's state of health. Their interpretation is usually embedded in a diagnostic framework, mainly because very few of them are specific for a particular disease. The arrival of the genome age seems to have promised that we will be able to refine biomarker analysis to a level where it can, on its own, diagnose disease, predict the best form of therapy for an individual and monitor its effects. The challenge is formidable, and proteomics plays a key role in taking it on. Genomic changes are relatively static, whereas the proteome is dynamic, reflecting physiological and pathological changes much more acutely and accurately. Proteomic biomarker research focuses on the following main areas. (i) The identification of new targets for therapeutic intervention. This approach examines the tumour cells directly and often overlaps with the intentions and methods described above. (ii) The identification of markers that permit early detection of disease, better stratification and are of prognostic value. These molecules could be produced by the tumour itself, or reflect the host's reaction to the tumour. This approach mostly examines body fluids. A crucial question is how large a tumour mass is detectable, and how does it compare with imaging methods, whose current detection limit is around one cubic centimetre of tumour volume. Studies with mice bearing human tumour xenografts suggest that the host response to the tumour predominates the biomarker pattern [57] , thus giving hope that even very small or disseminated tumours may be amplified and detectable through the host response. (iii) Markers for the monitoring of response to therapy. This aspect is of rapidly growing importance with the advent of non-cytotoxic drugs that cannot be monitored by clinical parameters alone, e.g. angiogenesis or cell cycle inhibitors.
Biomarker research faces several big challenges. One is the biological variability of patients' samples, which reflect the compound picture of variables stemming from differences in age, sex, exercise, diet, circadian rhythm, etc. Furthermore, just as the 'single gene -single function' relationship does not exist, a 'single marker -single disease' correlation is very unlikely. Thus we have to look for diagnostic patterns, which are mass peaks in the case of MS-based approaches. This task requires the development of new bioinformatics tools that can extract such patterns from data full of biological noise and individual variability, reliably recognize them in different samples where the patterns may be slightly changed and eventually cross-correlate them with other parameters related to the patients' health and treatment status. Such efforts are underway [58] [59] [60] [61] [62] [63] , but more development work will be needed to generate robust software that can handle such data. In fact, a recent controversy concerning the validity of a highly acclaimed study on biomarkers for the early detection of ovarian cancer [64] is in great part a debate about data handling and statistical evaluation [65] .
Another problem is the huge dynamic range of protein concentrations in tissues and body fluids, which in plasma for instance exceeds 11 orders of magnitude [66] . Thus any move towards a somewhat exhaustive analysis requires a large degree of pre-fractionation, highly specific reagents and sophisticated instrumentation. Even the use of less complex body fluids, such as urine, still requires separation in order to produce good data [67] .
Thus sample handling and preparation is crucial. Although plasma patterns are much more stable, many studies examine serum which, depending on the clotting time, yields a rather variable pattern that can seriously compromise reproducibility [67] . It should also be noted that the majority of MS-based methods detect smaller peptides with higher sensitivity, and hence are biased towards a mass range between 1-10 kDa. However, in this respect, they complement 2DGE-based methods, which do not resolve such small proteins.
Finally, any method used in the daily clinical routine must be simple, robust, affordable and amenable to automation and high throughput. In principle, one could use proteomics to find biomarkers, make antibodies and return to the immunological assays firmly established in the clinical laboratory. Unfortunately, none of the proteomic biomarker discovery methods intrinsically reveals the identity of the protein behind the mass peak that constitutes the marker. The coupling of marker discovery with their actual identification is a current quest in the field. We briefly review the currently championed MS-based biomarker discovery methods.
SELDI (surface-enhanced laserdesorption-ionization)-TOF (time-of-flight) MS
This technology combines sample fractionation on a chip integrated with MALDI-TOF MS analysis [68] . The sample is spotted onto a chip that has a specially modified surface that, similar to chromatographic matrices, retains a subset of proteins and peptides. As in any one-dimensional separation, the resolving power is limited. Hence careful optimization using different chip surfaces and conditions is necessary to achieve the best results for a particular set of samples. The chip is then directly analysed by MALDI-TOF. The procedure and instrumentation is simple and amenable to non-expert use and automation. Consequently, numerous reports on its use for biomarker discovery in a variety of different tumours have been published [69] . In particular, SELDI-TOF has been applied to analyse cancers of the prostate [70, 71] , ovary [64] , breast [72, 73] , lung [74, 75] , kidney [63, 76] , bladder [77] , pancreas [78] , liver [79] , colon [80] , endometrium [81] , cervix [82] , melanoma [83] and lymphoma [84] . In general, biomarker patterns were found that, where applicable, were superior in sensitivity and specificity compared with single markers currently used. This is very promising, although most studies are small and need validation by larger scale, multicentre studies and better statistical analyses. Monitoring therapeutic responses, the method could distinguish breast cancer patients before and after surgery, and both cohorts from healthy individuals [85] . However, it could not detect response to chemotherapy, probably because only one single mass peak was found to correlate with treatment [86] .
Particularly interesting are attempts to use SELDI-TOF on microdissected tumour cell lysates [80, 87, 88] . By comparison with plasma samples, this would permit the determination of whether a marker originates from the tumour itself or is part of the host response. This is an important question. The validity of such comparisons crucially depends on the ability to mine deeply both tissue and plasma proteomes across a comparable dynamic range, which is out of the reach of current methods. This is an example where the ease of use of SELDI-TOF may lure us into giving directions without knowing the map. Another example is the assignment of identifications based on peptide mass alone, which cannot be justified given the low mass accuracy of the current SELDI-TOF. Improvements are underway by combining the SELDI source with a high-performance MS/ MS analyser capable of peptide sequencing [89] . A more difficult problem is the poor comparability between studies [90] , which may be due to differences in the protocol, mass calibration, mass inaccuracy and data processing. These shortcomings are currently being addressed by improvements in hardware and software as well as attempts towards protocol standardization [68] .
LC (liquid chromatography)-MS/MS
This approach uses chromatography to pre-fractionate samples before MS analysis. It is more laborious and requires experienced personnel, but is readily interfaced with MS/MS instruments permitting direct peptide identification. Its resolving power can be dramatically enhanced by multi-dimensional LC separation procedures, such as MudPIT [91] , but the cost is limited throughput and the requirement for highly specialized MS facilities with dedicated bioinformatics support to handle the vast stream of raw data. A variation of MudPIT using isoelectric focussing in the first dimension instead of ion-exchange chromatography identified not only biomarker patterns, but also 22 of the corresponding proteins that were elevated in malignant breast cancer cells [92] . The same group reported similar approaches to investigate ovarian cancer [93] and metastasis-associated proteins [94] .
CE (capillary electrophoresis)-MS
This is a younger technology, combining the high separation power of CE with the high resolution and sensitivity of TOF MS. Solving the technical obstacle of interfacing CE with MS has opened the door to a method that can reliably resolve >1000 peptides by CE retention time and accurate mass with medium throughput [62] . It also permits the direct identification of selected biomarkers via their sequence using a tandem MS setup. So far, this method has mainly been applied to urine samples and used for the diagnosis and stratification of renal diseases [95] . However, it could also detect graft versus host disease several days before the clinical onset, and distinguish it from opportunistic infections [96] . Applications to the diagnosis of bladder cancer are underway with very encouraging results.
Imaging MS
The cell is spatially highly organized, a feature which we currently ignore. MALDI uses a laser to ionize the sample, offering the opportunity to take MS measurements directly from thin tissue sections, thus combining mass information with spatial resolution. This method is very new, but already able to visualize 500-1000 individual protein signals within a mass range from 2000 to over 200 000 Da [97] . These mass signals correlate with protein distribution within a specific region of the tissue sample allowing the reconstruction of images of protein expression within the sample. Profiling and imaging MS has been applied to diseased tissues, including human nonsmall cell lung tumours [98] , gliomas [99] and breast tumours [100] . These studies have resulted in identification of both disease-state and patient-prognosis-specific protein patterns, and can be expected to add a new dimension to histopathological analysis.
THE IMMUNE RESPONSE TO CANCER
As described above, many of the changes captured by proteomics actually correspond to the reaction of the host to the tumour. Inflammation and immunological reactions play a major role both as predisposing factors as well as defence mechanisms against tumours [101, 102] . Although there is little doubt about the existence of TAAs (tumour-associated antigens) and immune responses against them, there is no agreement about which TAAs should be targeted for cancer immunotherapy [103, 104] . Here, the identification of the antigens naturally involved in tumour immunity could provide decisive insight, and proteomics is well poised to assist. Two main approaches have been taken, one is the identification of peptide antigens presented by the MHC to the immune system, the other is the identification of the TAA protein targets of antibodies.
MHC-presented peptide antigens
MHC-bound peptides can be recovered by elution with mild acids from intact tumour cells or through immunopurification of MHC molecules from lysed cells [105] . More efficient procedures are the expression of tagged MHC for easier purification [106] , or soluble MHC proteins that are secreted, including their bound peptides, and that can be harvested from the growth medium in large quantities [107, 108] . Typically, MHC peptides are fractionated by chromatography and assayed for their ability to stimulate T-cell responses. Active fractions are then further separated and identified by LC-MS/MS [109] . As such studies require large amounts of material, they have been conducted mostly with cultured cells. Only a handful of studies has examined MHC peptides from primary tumour material [110] [111] [112] . Encouragingly, meaningful TAAs were found, for instance a BCR-ABL-specific peptide presented by CML cells [110] . A systematic approach [111] combines the isolation and identification of MHC-bound peptides from primary tumour cells with gene expression profiling, to select those MHC peptides which are likely to represent true TAAs. These are then tested for eliciting T-cell responses in immunization experiments. A recent refinement was the introduction of mass labels that permit the MS-based quantitative comparison of MHC-presented peptides between two different samples, including tissues [113] .
Antibodies against TAAs
Many cancer patients mount an immune response, producing antibodies against their tumour. The targets of these antibodies could be useful for diagnostic and therapeutic purposes, and hence both genetic [114] and proteomic [115] approaches have been developed. A typical proteomics approach uses 2DGE to produce Western blots which are probed with patients' sera. Proteins selectively detected by cancer patients', but not control, sera are subsequently identified by MS. This method has identified antigens recognized by the immune system in cancers of the pancreas [116] , kidney [117] , lung [118] , breast [119] and liver [120] . All studies succeeded in identifying potentially useful antigens, but their number was very small, and they represented abundant proteins, suggesting that the method could benefit from an enhancement of sensitivity. This may be achieved by using patients' sera to immunoprecipitate antigens before 2DGE and MS analysis [121] , resulting in a larger number of identified TAAs, although these were still mainly from highly abundant proteins.
An interesting idea is to employ protein microarrays in order to identify TAAs. For this purpose LoVo colon adenocarcinoma cell lysates were separated into 1760 fractions, arrayed and probed with individual sera from 15 patients with colon cancer, 15 with lung cancer and 15 healthy subjects [122] . Thirty-nine fractions showed significantly enhanced reactivity with sera from patients with colon cancer relative to healthy controls, and colon cancer sera displayed a distinct pattern of reactivity compared with lung cancer. One fraction that reacted with nine out of 15 colon cancer sera was analysed by MS, leading to the identification of UCH-L3 (ubiquitin Cterminal hydrolase isozyme 3) as a constituent. Western blot validation detected antibodies to UCH-L3 in 19 out of 43 sera from patients with colon cancer, but in none of the 54 control sera from healthy subjects or patients with benign colon adenomas or lung cancer. Thus this method is promising in identifying highly specific TAAs.
A variation of this approach is to start from antibody libraries to discover new TAAs. Screening a single domain antibody library against the A549 lung carcinoma cell line, a tumour-cell-specific antibody was recovered, and its cognate antigen was subsequently identified by MS as CEACAM6 (carcinoembryonic antigen-related celladhesion molecule 6) [123] .
Using human antibody gene diversity libraries more than 90 monoclonal antibodies were developed that can specifically recognize and enter prostate cancer cells, but not control cells [124] . These antibodies could deliver cargo such as liposomes into prostate cancer cells, and some antibodies inhibited proliferation. Thus these antibodies will be useful for targeted therapy. As their antigens are likely to be involved in tumour-specific protein internalization, identifying them could pave the way for delivering therapeutic agents into tumour cells.
OUTLOOK
Although proteomics has established itself as a valuable tool for basic cancer research, it is less clear how it can best be implemented in clinical research. The current state has been aptly compared with the Wright brothers' first heavier-than-air flights [125] . However, although the Wright brothers had one aircraft to improve, we are facing a whole fleet of potentially very capable machines and methods that need some tuning when launched into clinical use. How do we choose? There is a cost issue. Proteomics is expensive and requires highly specialized facilities with skilled staff. Clearly, a clinical method must be robust and capable of reasonably high throughput at reasonable cost. How much can we afford to compromise? MS instrumentation has been improving in quantum leaps in recent years both in respect to capability and user friendliness. We have progressed from flying-by-the-seats-of-our-pants to fly-by-wire. But, as flying becomes easier, we cover greater distances, and even more rely on the pilot to be able to navigate the best course to ever more ambitious destinations. Besides the pilot's skill, the most crucial navigation aids are provided by bioinformatics equipping us with most of the tools we need for data handling and interpretation. Even if the implementation of full proteomics studies into clinical laboratories is beyond the scope of current science, proteomics is already delivering tangible benefits, unlocking our understanding of the underlying science and identifying new targets and markers that can be exploited by currently more robust technologies. A task for the future is to create standards that make proteomics comparable between laboratories and are necessary for the large scale multicentre studies required for clinical validation. Efforts are underway [126] . A bigger challenge will be to integrate proteomics with all the information from the other '-omics', in particular genomics and metabolomics. This will allow us to obtain the holistic molecular view of pathogenetic processes, which enables their early recognition and the best selection of therapy tailored to the individual patient. Some of these benefits are shown in Figure 3 . We have only taken a few steps on This comparison summarizes the suitability of these technologies for the assessment of disease susceptibility, diagnosis, treatment and aftercare. Three dots, highly suitable; two dots, suitable; one dot, limited suitability. the road towards this goal, but "The secret of success is constancy to purpose" (Benjamin Disraeli).
